Altimmune, Inc. (ALT) Profit Margins
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALTAltimmune, Inc.Follow ALT — free
—
Price chart with a free account
- Market cap
- 412.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2011 Dec 11 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 82.8% | — | — | — | — | — | |
| Operating margin | -48.3% | -484.7% | -414.6% | -370.0% | -2197.6% | -22518.5% | -515860.0% | -230461.0% | — | |
| Net margin | -15.6% | -432.3% | -379.2% | -353.7% | -2201.6% | -20762.2% | -475295.0% | -214861.0% | — | |
| FCF margin | -32.5% | -189.3% | -100.3% | -165.5% | -2048.9% | -17806.8% | — | -164746.3% | — |
USD millions · SEC XBRL
Every figure on this page comes from Altimmune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.